伊布替尼联合利妥昔单抗治疗惰性临床型套细胞淋巴瘤(IMCL-2015):一项多中心、开放标签、单臂、II期试验
这项多中心单臂开放标签II期试验纳入50例未经治疗、符合惰性临床型标准的套细胞淋巴瘤患者,给予伊布替尼560 mg每日一次联合利妥昔单抗375 mg/m²共8剂。12周期后总缓解率84%(95%CI 74-94),完全缓解率80%(95%CI 69-91),外周血MRD不可测率87%(95%CI 77-97)。2年时35例可评估患者中24例(69%)因MRD不可测而停用伊布替尼。
要点
- 12周期后完全缓解率80%(95%CI 69-91),总缓解率84%(95%CI 74-94)。
- 外周血MRD不可测率87%(95%CI 77-97)。
- 2年时35例可评估患者中24例(69%)因MRD不可测停用伊布替尼。
核心结论
- 一线伊布替尼联合利妥昔单抗在惰性临床型套细胞淋巴瘤中取得高完全缓解率和MRD不可测率。
- 在MRD不可测的病例中停用伊布替尼似乎是合适的,但TP53突变病例除外。
研究设计与样本
- 多中心、单臂、开放标签、II期研究,采用两阶段设计,在12个西班牙GELTAMO中心开展(ClinicalTrials.gov标识:NCT02682641)。
- 纳入既往未经治疗、符合惰性临床型标准的套细胞淋巴瘤患者:无疾病相关症状、非母细胞样变异型、Ki-67<30%、最大肿瘤直径≤3 cm。
- 同时招募白血病样非结节型和结节型亚型。
- 患者接受伊布替尼560 mg每日一次和利妥昔单抗375 mg/m²共8剂。
- 主要终点为按Lugano标准评估的12周期后完全缓解率。
主要发现
- 共入组50例套细胞淋巴瘤患者(男性66%;中位年龄65岁)。
- 12周期治疗后42例(84%;95%CI 74-94)达总缓解,其中40例(80%;95%CI 69-91)达完全缓解。
- 外周血MRD不可测者达87%(95%CI 77-97)。
- 2年时35例可评估患者中24例(69%)因MRD不可测而停用伊布替尼。
- 4例疾病进展,其中3例为非结节型套细胞淋巴瘤,入组时携带高基因组复杂性和TP53突变;除1例严重再生障碍性贫血外未见意外毒性。
关键数值与推荐
- 惰性临床型定义标准:无疾病相关症状、非母细胞样变异型、Ki-67<30%、最大肿瘤直径≤3 cm。
- 伊布替尼剂量560 mg每日一次,利妥昔单抗375 mg/m²共8剂。
- MRD持续不可测时伊布替尼可在2年后停用。
- 主要终点为12周期后按Lugano标准评估的完全缓解率。
临床怎么用
- 作者认为一线伊布替尼联合利妥昔单抗在惰性临床型套细胞淋巴瘤中取得高完全缓解率和MRD不可测率。
- 作者认为在MRD不可测的病例中停用伊布替尼似乎是合适的,但TP53突变病例除外。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The need for an individualized management of indolent clinical forms in mantle cell lymphoma (MCL) is increasingly recognized. We hypothesized that a tailored treatment with ibrutinib in combination with rituximab (IR) could obtain significant responses in these patients. METHODS: This is a multicenter single-arm, open-label, phase II study with a two-stage design conducted in 12 Spanish GELTAMO sites (ClinicalTrials.gov identifier: NCT02682641). Previously untreated MCL patients with indolent clinical forms defined by the following criteria were eligible: no disease-related symptoms, nonblastoid variants, Ki-67 < 30%, and largest tumor diameter ≤ 3 cm. Both leukemic non-nodal and nodal subtypes were recruited. Patients received ibrutinib 560 mg once daily and a total of eight doses of rituximab 375 mg/m2. Ibrutinib could be discontinued after 2 years in the case of sustained undetectable minimal residual disease (MRD). The primary end point was the complete response (CR) rate achieved after 12 cycles according to Lugano criteria. RESULTS: Fifty patients with MCL (male 66%; median age 65 years) were enrolled. After 12 cycles of treatment, 42 (84%; 95% CI, 74 to 94) patients had an overall response, including 40 (80%; 95% CI, 69 to 91) with CR. Moreover, undetectable MRD in peripheral blood was achieved in 87% (95% CI, 77 to 97) of cases. At 2 years, 24 of 35 evaluable patients (69%) could discontinue ibrutinib because of undetectable MRD. Four patients had disease progression; three were non-nodal MCL and carried high genomic complexity and TP53 mutations at enrollment. No unexpected toxicity was seen except one patient with severe aplastic anemia. CONCLUSION: Frontline IR combination achieves a high rate of CRs and undetectable MRD in indolent clinical forms of MCL. Discontinuation seems appropriate in cases with undetectable MRD, except for TP53-mutated cases.
引用
- Giné E, de la Cruz F, Jiménez Ubieto A, et al. Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial. J Clin Oncol. 2022. PMID: 35030036. doi:10.1200/JCO.21.02321
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。